• General Dermatology
  • Eczema
  • Alopecia
  • Aesthetics
  • Vitiligo
  • COVID-19
  • Actinic Keratosis
  • Precision Medicine and Biologics
  • Rare Disease
  • Wound Care
  • Rosacea
  • Psoriasis
  • Psoriatic Arthritis
  • Atopic Dermatitis
  • Melasma
  • NP and PA
  • Skin Cancer
  • Hidradenitis Suppurativa
  • Drug Watch
  • Pigmentary Disorders
  • Acne
  • Pediatric Dermatology
  • Practice Management

Funding secured for antibacterial-resistant acne treatment

Dermatology TimesDermatology Times, February 2019 (Vol. 40, No. 2)
Volume 40
Issue 2

Vyome Therapeutics Inc. announced in January that it secured $22 million in financing to, in part, support the development of its lead molecule, VB 1953, through phase two clinical trials for moderate to severe acne.


Vyome Therapeutics Inc. secured $22 million in financing to support the development of its lead molecule, VB 1953, through phase two clinical trials for moderate to severe acne. (Frank - stock.adobe.com)

Vyome Therapeutics Inc. announced in January that it secured $22 million in financing to, in part, support the development of its lead molecule, VB 1953, through phase two clinical trials for moderate to severe acne.

“The closing of Vyome’s Series D comes at a transformational time for the company, as we prepare to initiate a phase 2b clinical trial with our lead candidate, VB 1953, and as we establish the center of operations and headquarters in the United States through a corporate restructuring exercise,” said Venkateswarlu Nelabhotla (Venkat), chief executive officer of Vyome Therapeutics. “We see this investment as validation of Vyome’s innovative approach to efficient specialty pharmaceutical development and the ability of the company’s scientific platform to help solve the problem of microbial resistance in dermatology.”

VB 1953 is a topical bactericidal antibiotic candidate with a novel mechanism of action that is designed to reduce inflammation. It is designed to treat antibiotic resistant P. acnes strains in which a phase 2b clinical trial is planned. In preclinical studies, VB 1953 was shown to be active against clindamycin-resistant P. acnes bacteria. It was shown to have a low emergence of resistance and to reduce inflammation.

VB 1953 is delivered with a microtechnology gel system that ensures the drug is retained at the site of infection and minimizes systemic exposure.

Related Videos
© 2024 MJH Life Sciences

All rights reserved.